Zotepine for schizophrenia

DeSilva, P; Fenton, Mark; Rathbone, John

doi:10.1002/14651858.cd001948.pub2

Cited by 17 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Next, the reference lists of review articles and meta-analyses were examined to identify possible studies not found during the online search. For example, we checked the reference lists of the latest systematic reviews carried out by the Cochrane Collaboration which involved AAs available in the market [12][13][14][15][16][17][18][19] .…”

Section: Search Strategiesmentioning

confidence: 99%

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics

Oliveira

Nunes

Coutinho

et al. 2009

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

Section: Search Strategiesmentioning

confidence: 99%

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics

Oliveira

Nunes

Coutinho

et al. 2009

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…It is also less likely to induce extrapyramidal side effects compared with typical antipsychotics (Meyer‐Lindenberg et al. , 1997; DeSilva et al. , 2006; Hashimoto et al.…”

Section: Introductionmentioning

confidence: 99%

“…Zotepine has an atypical profile and is effective against negative (such as affective flattening, aboulia and social withdrawal) and positive (such as hallucination and delusion) symptoms, as well as cognitive deficits of schizophrenia. It is also less likely to induce extrapyramidal side effects compared with typical antipsychotics (Meyer-Lindenberg et al, 1997;DeSilva et al, 2006;Hashimoto et al, 2006). In addition, an open pilot study demonstrated the rapid and beneficial therapeutic effects of zotepine in patients with severe mania (Amann et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex

Yamamura

Ohoyama

Hamaguchi

et al. 2009

British J Pharmacology

View full text Add to dashboard Cite

Background and purpose:The atypical antipsychotic drug, zotepine, is effective in treatment of schizophrenia and acute mania, but the incidence of seizures during treatment is higher than with other antipsychotics. In addition, the mechanisms underlying the clinical actions of zotepine remain uncharacterized. Experimental approach: The effects of intraperitoneal administration of zotepine and haloperidol on the extracellular levels of noradrenaline, dopamine, 5-HT, GABA, and glutamate in the medial prefrontal cortex (mPFC) were compared. Neuronal activities induced by each drug in the ventral tegmental area (VTA), locus coeruleus (LC), dorsal raphe nucleus (DRN) and mediodorsal thalamic nucleus (MTN) were also analysed. Key results: Haloperidol did not affect extracellular neurotransmitter levels in the mPFC. In contrast, zotepine activated neuronal activities in all nuclei and increased the extracellular levels of noradrenaline, dopamine, GABA, and glutamate in the mPFC, but not 5-HT levels. The zotepine-stimulated neuronal activity in the VTA, LC, DRN and MTN enhanced the release of dopamine, noradrenaline, 5-HT, glutamate and GABA in the mPFC, although the enhanced GABAergic transmission possibly inhibited noradrenaline, dopamine and 5-HT release. The other afferent to mPFC, which releases dopamine and noradrenaline, was partially insensitive to GABAergic inhibition, but possibly received stimulatory AMPA/glutamatergic regulation from the MTN. Conclusions and implications:Our results indicated that the positive interaction between prefrontal catecholaminergic transmission and AMPA/glutamatergic transmission from MTN might explain the regulatory effects of zotepine on neurotransmitter release. A mechanism is suggested to account for the pharmacological profile of this atypical antipsychotic and for its pro-convulsive action.

show abstract

“…A Cochrane review had previously concluded that there were no clear differences between zotepine and other second generation antipsychotic drugs (DeSilva 2006). This statement is compatible with our finding that zotepine may be as effective [or ineffective] as risperidone and remoxipride.…”

Section: Discussionmentioning

confidence: 99%

“…Zotepine is a second generation antipsychotic drug with a high affinity for human D1-like (D1, D5) and D2-like (D2, D3, D4) dopamine receptors and serotonin subtypes (5HT2a, 5HT2c, 5HT6, 5HT7; Leysen 1993, Roth 1994, Needham 1996). It also inhibits norepinephrine re-uptake and it is claimed to be particularly effective for negative symptoms (DeSilva 2006).…”

Section: Introductionmentioning

confidence: 99%